Precision medicine necessitates precision research, which necessitates getting highly specific biospecimens to researchers on demand, in alignment with their demand. Researchers shouldn’t have to adjust their research to whatever specimens are available; supply needs to fit the research.
Looking back, it’s ironic that we named our company LaunchPad Medical. Our inspiration for the name came from our plan to take challenging ideas and materials and “launch” them into the medical space to revolutionize healthcare. But it never dawned on me to take our research to the International Space Station (ISS).
Organizations and their leaders often focus on what needs to improve, but research shows there is more to be gained from a strengths-based approach. Coaching around strengths yields greater optimism and success.
With the right preparation and investments, entering the federal government market can lead to considerable growth and visibility for your company. Consider the following tips for increased chances of success.
The medical device market is about to succumb to a raft of substantial international regulatory changes, starting with Europe’s MDR in May 2020, as public pressure and industry authorities call for greater accountability for patient safety.
Much like in many other areas of the drug development continuum, the focus now in the cold chain is on data and how it can be unlocked and analyzed in real time to save money, time, and resources — while also better ensuring patient safety.
As the industry’s appetite for creating and using data-driven insights to improve clinical outcomes continues to grow, so does the need to integrate and validate disparate data sources. Efforts to impose greater consistency and rigor should be welcomed by all.